We must move breast cancer advocacy to the next level, beyond screening for cancers that are already there, even beyond the cure, to finding the cause, writes Dr. Susan Love.

TUESDAY, Feb. 7 (HealthDay News) -- A drug used to prevent breast cancer in women at high risk for the disease appears to cause bone loss in some postmenopausal women, a new study finds.

Despite expert guidelines and scientific evidence to the contrary, a third of U.S. primary care physicians believe ovarian cancer screening is effective and many would offer it to patients

As a prominent breast cancer researcher and activist, Susan Love is no stranger to the Susan G. Komen Foundation. Love runs a breast cancer research foundation that bears her name, and she organized the Army of Women , more than 360,000 women to whom breast cancer researchers can blast out requests for subjects. But the Komen Foundation is so entrenched in the world of breast cancer fundraising ...

Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research, personalized medicine and the molecular diagnostics of cancer, today announced that the National Cancer Institute awarded two Small Business Innovative Research contracts to develop novel lung cancer tests based on the isolation of mutation-bearing Circulating Tumor Cells from whole blood.

NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Abraxane (Breast Cancer) – Analysis and Forecasts to 2020 http://www.reportlinker.com/p0657216/Abraxane-Breast-Cancer-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PathologyAbraxane ...

MONDAY, Feb. 6 (HealthDay News) -- Treatment with three relatively new cancer drugs may be linked to a slightly increased risk of death, a new analysis suggests.

Perhaps too much emphasis is placed on looking for existing breast cancer when the search should focus on prevention and the possibility of finding a vaccine.

The president of Memorial Sloan-Kettering Cancer Center is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.

The president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.